SCHEMBL11973157

SCHEMBL11973157

Nc1cccnc1S(=O)(=O)Nc1cccc2cccnc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 13/20 0.73
TDP1 Q9NUW8 7/20 0.73
KMT2A Q03164 6/20 0.73
MEN1 O00255 5/20 0.73
NFKBIA P25963 3/20 0.73
RELA Q04206 2/20 0.73
GLO1 Q04760 7/20 0.63
AGTR1 P30556 2/20 0.63
G6PD P11413 1/20 0.63
METAP2 P50579 1/20 0.63
METAP1 P53582 1/20 0.63
PAX8 Q06710 1/20 0.63
ATM Q13315 1/20 0.63
HTT P42858 2/20 0.60
ALOX15 P16050 1/20 0.60
MITF O75030 1/20 0.59
S1PR4 O95977 1/20 0.59
ALDH1A1 P00352 1/20 0.59
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31676665 0.84 SLC40A1 (1.00) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL460773 0.84 SLC40A1 (1.00) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL27214286 0.83 SLC40A1 (0.72) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL30925535 0.83 SLC40A1 (0.73) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL30925443 0.83 SLC40A1 (0.77) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL30925489 0.83 SLC40A1 (0.67) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL27214250 0.83 SLC40A1 (0.77) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL30925538 0.83 TDP1 (0.73) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL30925505 0.83 SLC40A1 (0.77) SLC40A1TDP1KMT2AMEN1NFKBIA
SCHEMBL27214222 0.83 SLC40A1 (0.77) SLC40A1TDP1KMT2AMEN1NFKBIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103492028-B Sulfonaminoquinoline hepcidin antagonists 维福(国际)股份公司 2017-02-08 CN disclosed
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 US disclosed
CN-103492028-A Novel sulfonaminoquinoline hepcidin antagonists VIFOR INT AG 2014-01-01 CN disclosed
EP-2675526-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS Vifor (International) AG (CH) 2013-12-25 EP disclosed
WO-2012110603-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 WO disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885TDP1 4862/4885KMT2A 3298/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885TDP1 4862/4885KMT2A 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.